Key result
A 64-year-old man diagnosed with a rare blastoid mantle cell lymphoma presenting as an isolated cecal mass received 4 cycles of bendamustine and rituximab but ultimately required terminal extubation due to clinical deterioration.
Why the study?
Blastoid mantle cell lymphoma is a rare, aggressive lymphoma subtype where gastrointestinal involvement rarely presents as an isolated lesion.
Case Report (n=1)
No
Blastoid mantle cell lymphoma can rarely present as an isolated gastrointestinal mass, highlighting the need to consider it in the differential diagnosis of isolated GI lesions.
Isolated cecal masses warrant lymphoma consideration in differentials; extends blastoid mantle cell lymphoma phenotypes but leaves broader implications open.
Blastoid mantle cell lymphoma (B-MCL) is a rare and aggressive subtype of B-cell non-Hodgkin lymphoma characterized by a high proliferation index and poor prognosis. Gastrointestinal (GI) involvement, which is common in systemic mantle cell lymphoma (MCL), rarely presents as an isolated lesion. Herein, we describe a unique case of B-MCL presenting as an isolated cecal mass. The patient experienced acute-onset abdominal pain and melena and was found to have cecal wall thickening on imaging, with regional lymphadenopathy. Colonoscopy revealed a large ulcerated polypoid lesion in the cecum, and histopathology confirmed the diagnosis of B-MCL. The patient completed 4 cycles of bendamustine/rituximab regimen but was terminally extubated due to clinical deterioration. Although infrequent, MCL should be considered in the differential diagnosis of isolated GI masses. This case adds to the limited literature on B-MCL, which could potentially help with the formulation of diagnostic and treatment algorithms for this rare pathology.
No takes yet. Share an insight, caveat, or question.
Bathobakae et al. (2025) conducted a case report in Blastoid Mantle Cell Lymphoma (n=1). Bendamustine and rituximab was evaluated. A 64-year-old man diagnosed with a rare blastoid mantle cell lymphoma presenting as an isolated cecal mass received 4 cycles of bendamustine and rituximab but ultimately required terminal extubation due to clinical deterioration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: